Taking on board higher near-term expenses
22/06/22 -"However, these expenses are investment into growth and should continue to support Astra’s sector-leading top-line growth in the coming years. Overall, our positive stock recommendation on the pharma ..."
Pages
65
Language
English
Published on
22/06/22
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum